Acquisition Pending

AbbVie acquisition of Apogee Therapeutics

US$11bn equity value

Announced 22 Jun 2026 · NASDAQ: APGE · US$135.11 cash per share

Advisers

Apogee Therapeutics

Target

Financial adviser
Legal adviser
Fairness opinion

AbbVie

Acquirer

Financial adviser
Legal adviser
Target
Apogee Therapeutics
Acquirer
AbbVie
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Dermatology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.